Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
43.1M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
32.6M
-
Shares change
-
-2.17M
-
Total reported value, excl. options
-
$396M
-
Value change
-
-$27.7M
-
Put/Call ratio
-
0
-
Number of buys
-
26
-
Number of sells
-
-32
-
Price
-
$12.13
Significant Holders of Repare Therapeutics Inc. - Common Shares, no par value (RPTX) as of Q3 2022
82 filings reported holding RPTX - Repare Therapeutics Inc. - Common Shares, no par value as of Q3 2022.
Repare Therapeutics Inc. - Common Shares, no par value (RPTX) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.6M shares
of 43.1M outstanding shares and own 75.83% of the company stock.
Largest 10 shareholders include BVF INC/IL (8.29M shares), ORBIMED ADVISORS LLC (3.32M shares), Deep Track Capital, LP (3.13M shares), CHI Advisors LLC (3.07M shares), Redmile Group, LLC (2.68M shares), ARK Investment Management LLC (2.63M shares), MPM ASSET MANAGEMENT LLC (2.24M shares), T. Rowe Price Investment Management, Inc. (1.76M shares), BIOIMPACT CAPITAL LLC (1.64M shares), and Artal Group S.A. (700K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.